Literature DB >> 25629531

Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.

Dinesh Kannabhiran1, John Lee, Joseph E Schwartz, Rex Friedlander, Meredith Aull, Thangamani Muthukumar, Sean Campbell, David Epstein, Surya V Seshan, Sandip Kapur, Vijay K Sharma, Manikkam Suthanthiran, Darshana Dadhania.   

Abstract

BACKGROUND: Characteristics of pretransplant antibodies directed at donor human leukocyte antigen (HLA) donor-specific antibodies (DSA) associated with adverse outcomes in kidney transplant recipients are being elucidated but uncertainties exist.
METHODS: We prospectively screened pretransplant sera from 543 kidney recipients using single antigen bead assays and identified 154 patients with and 389 without DSA. We investigated the association of DSA features to acute rejection and graft failure.
RESULTS: One-year acute rejection incidence was higher in DSA-positive group (P < 0.001), primarily due to antibody-mediated rejection (AMR, 13% vs. 1.8%, P < 0.001) and not T cell-mediated rejection (ACR, 5% vs.6%, P = 0.65). The sum of mean fluorescence intensity of DSA (DSA MFI-Sum) of 6,000 or higher (OR, 18; 95% CI, 7.0-47; P < 0.001) and the presence of DSA against both HLA class I and II (OR, 39; 95% CI, 14-106; P < 0.0001) predicted 1-year AMR, independent of other covariates. Calculated panel reactive antibody and a positive flow cytometry cross-match result were associated with AMR by bivariate analysis but neither was an independent predictor in a multivariable regression analysis that included DSA-MFI-Sum or HLA DSA class. In multivariable Cox proportional hazards models, the covariate-adjusted hazard ratio for graft failure was 2.03 (95%CI, 1.05-3.92; P = 0.04) for DSA MFI-Sum of 6,000 or higher and 2.23 (95% CI, 1.04-4.80; P = 0.04) for class I and II DSA. Prediction of graft failure was not independent of AMR.
CONCLUSION: Our study suggests that DSA MFI-Sum and HLA class of DSA are characteristics predictive of AMR and graft failure. The elevated risk of graft failure in those with the identified features of DSA is attributable to increased risk of AMR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25629531      PMCID: PMC4729299          DOI: 10.1097/TP.0000000000000511

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  35 in total

1.  Using real data for a virtual crossmatch.

Authors:  Andrea A Zachary; Jeffrey T Sholander; Julie A Houp; Mary S Leffell
Journal:  Hum Immunol       Date:  2009-06-12       Impact factor: 2.850

2.  C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation.

Authors:  Julie M Yabu; John P Higgins; Ge Chen; Flavia Sequeira; Stephan Busque; Dolly B Tyan
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

3.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.

Authors:  G Chen; F Sequeira; D B Tyan
Journal:  Hum Immunol       Date:  2011-07-18       Impact factor: 2.850

4.  Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes.

Authors:  Neeraj Singh; Arjang Djamali; David Lorentzen; John D Pirsch; Glen Leverson; Nikole Neidlinger; Barbara Voss; Jose R Torrealba; R Michael Hofmann; Jon Odorico; Luis A Fernandez; Hans W Sollinger; Milagros Samaniego
Journal:  Transplantation       Date:  2010-11-27       Impact factor: 4.939

5.  No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report.

Authors:  Caner Süsal; Jörg Ovens; Khaled Mahmoud; Bernd Döhler; Sabine Scherer; Andrea Ruhenstroth; Thuong Hien Tran; Andreas Heinold; Gerhard Opelz
Journal:  Transplantation       Date:  2011-04-27       Impact factor: 4.939

6.  Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients.

Authors:  Clifford Chin; Ge Chen; Flavia Sequeria; Gerald Berry; Stephanie Siehr; Daniel Bernstein; David Rosenthal; Olaf Reinhartz; Dolly Tyan
Journal:  J Heart Lung Transplant       Date:  2010-10-15       Impact factor: 10.247

7.  Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.

Authors:  Carmen Lefaucheur; Alexandre Loupy; Gary S Hill; Joao Andrade; Dominique Nochy; Corinne Antoine; Chantal Gautreau; Dominique Charron; Denis Glotz; Caroline Suberbielle-Boissel
Journal:  J Am Soc Nephrol       Date:  2010-07-15       Impact factor: 10.121

8.  Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.

Authors:  Kwaku Marfo; Maria Ajaimy; Adriana Colovai; Liise Kayler; Stuart Greenstein; Michelle Lubetzky; Anjali Gupta; Layla Kamal; Graciela de Boccardo; Peter Masiakos; Milan Kinkhabwala; Enver Akalin
Journal:  Transplantation       Date:  2014-11-27       Impact factor: 4.939

9.  Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.

Authors:  Patrizia Amico; Gideon Hönger; Michael Mayr; Jürg Steiger; Helmut Hopfer; Stefan Schaub
Journal:  Transplantation       Date:  2009-06-15       Impact factor: 4.939

10.  Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients.

Authors:  Afzal Nikaein; Wida Cherikh; Karen Nelson; Timothy Baker; Sue Leffell; Laurine Bow; Debbie Crowe; Ketra Connick; Mary Ann Head; Malek Kamoun; Pam Kimball; Ellen Klohe; Harriet Noreen; Lorita Rebellato; Tom Sell; Karen Sullivan; Geoffrey Land
Journal:  Transplantation       Date:  2009-02-27       Impact factor: 4.939

View more
  10 in total

1.  Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.

Authors:  Elaine Y Cheng; Matthew J Everly; Hugo Kaneku; Nubia Banuelos; Laura J Wozniak; Robert S Venick; Elizabeth A Marcus; Suzanne V McDiarmid; Ronald W Busuttil; Paul I Terasaki; Douglas G Farmer
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies.

Authors:  Carrie A Schinstock; Andrew J Bentall; Byron H Smith; Lynn D Cornell; Matthew Everly; Manish J Gandhi; Mark D Stegall
Journal:  Am J Transplant       Date:  2018-12-15       Impact factor: 8.086

Review 3.  Interpreting Anti-HLA Antibody Testing Data: A Practical Guide for Physicians.

Authors:  Carrie A Schinstock; Manish J Gandhi; Mark D Stegall
Journal:  Transplantation       Date:  2016-08       Impact factor: 4.939

4.  Factors at de novo donor-specific antibody initial detection associated with allograft loss: a multicenter study.

Authors:  Carrie A Schinstock; Darshana M Dadhania; Matthew J Everly; Byron Smith; Manish Gandhi; Evan Farkash; Vijay K Sharma; Milagros Samaniego-Picota; Mark D Stegall
Journal:  Transpl Int       Date:  2019-02-08       Impact factor: 3.782

5.  Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after heart transplantation.

Authors:  Osama Omrani; Moheeb Alawwami; Jehad Buraiki; Nedim Selimovic
Journal:  Ann Saudi Med       Date:  2018 Mar-Apr       Impact factor: 1.526

6.  A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation.

Authors:  Nicole Wittenbrink; Sabrina Herrmann; Arturo Blazquez-Navarro; Chris Bauer; Eric Lindberg; Kerstin Wolk; Robert Sabat; Petra Reinke; Birgit Sawitzki; Oliver Thomusch; Christian Hugo; Nina Babel; Harald Seitz; Michal Or-Guil
Journal:  BMC Immunol       Date:  2019-04-27       Impact factor: 3.615

7.  Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation.

Authors:  Audrey Uffing; Luis G Hidalgo; Ciaran McMullan; Jacqueline Perry; Edgar L Milford; Naoka Murakami; Melissa Y Yeung; Indira Guleria; Isabelle G Wood; Enver Akalin; Jamil Azzi; Anil K Chandraker; Leonardo V Riella
Journal:  Transplant Direct       Date:  2019-04-15

8.  Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients.

Authors:  Alexander H Morrison; Meera Gupta; Kelsey Lloyd; Jennifer Trofe-Clark; Mary Ann Lim; Christine Limonte; Matthew H Levine; Deirdre Sawinski; Malek Kamoun; Paige M Porrett
Journal:  Transplant Direct       Date:  2019-07-25

9.  Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays.

Authors:  Ana Navas; Juan Molina; María-Luisa Agüera; Ipek Guler; Aurora Jurado; Alberto Rodríguez-Benot; Corona Alonso; Rafael Solana
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

10.  Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study.

Authors:  David Shaffer; Irene D Feurer; Deborah Crowe; Heidi Schaefer
Journal:  Transplant Direct       Date:  2016-01-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.